 "Sun Pharma")
Strong growth in domestic and US markets helped India’s largest drugmaker Sun Pharmaceutical Industries report a net profit of Rs 1,444 crore in the first quarter of this financial year.
In the same period a year ago, the company had posted a net loss of Rs 1,655 crore owing to a drop in revenue and exceptional expenses.
Revenue from operations in the first quarter rose 29 per cent year-on-year and 14 per cent on a sequential basis to Rs 9,669 crore. Domestic business, which accounted for 34 per cent of the total turnover, rose 39 per cent and
In the same period a year ago, the company had posted a net loss of Rs 1,655 crore owing to a drop in revenue and exceptional expenses.
Revenue from operations in the first quarter rose 29 per cent year-on-year and 14 per cent on a sequential basis to Rs 9,669 crore. Domestic business, which accounted for 34 per cent of the total turnover, rose 39 per cent and
